Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 2, 2004 - Issue 4
Submit an article Journal homepage
24
Views
13
CrossRef citations to date
0
Altmetric
Review

In search of a small-molecule inhibitor for respiratory syncytial virus

Janet L Douglas Formerly Gilead Sciences. [email protected]
Pages 625-639 | Published online: 10 Jan 2014

References

  • Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am. J. Respir. Crit. Care Med. 161,1501–1507 (2000).
  • Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson U. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J. Infect. Dis. 183,16–22 (2001).
  • Knipe DM, Howley PM (Eds), Lippincott Williams and Wilkins, PA, USA (2001).
  • •Comprehensive review of respiratorysyncytial virus (RSV).
  • Falsey AR,Walsh EE. Respiratory syncytial virus infection in adults. Clin. Microbial Rev. 13,371–384 (2000).
  • Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the USA. J. Am. Med. Assoc. 289,179–186 (2003).
  • Dudas RA, Karron RA. Respiratory syncytial virus vaccines. Clin. Microbial Rev. 11,430–439(1998).
  • Anderson LJ, Parker RA, Strikas RL. Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children. J. Infect. Dis. 161,640–646 (1990).
  • American Academy of Pediatrics. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics 97,137–140 (1996).
  • Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J. Med. 329,1524–1530 (1993).
  • Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176, 1215–1224. (1997).
  • Impact-RSV study group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratroy syncytial virus infection in high-risk infants. Pediatrics 102,531–537 (1998).
  • Malley R, DeVincenzo J, Ramilo O, et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J. Infect. Dis. 178,1555–1561 (1998).
  • Rodriguez WJ, Gruber WC, Groothuis JR, et al. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics 100,937–942 (1997).
  • American Academy of Pediatrics. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 112,1442–1446 (2003).
  • Wyde PR Chemotherapy of respiratory viruses: prospects and challenges. Drug Resist. Updates 2,244–258 (1999).
  • Shigeta S. Recent progress in antiviral chemotherapy for respiratory syncytial virus infections. Expert Opin. Investig. Drugs. 9(2), 221–235 (2000).
  • Meanwell NA, Krystal M. Respiratory syncytial virus: recent progress towards the discovery of effective prophylactic and therapeutic agents. Drug Delivery Tech. 5, 241–252 (2000).
  • •Review of RSV prophylaxis and therapy.
  • Prince GA. An update on respiratory syncytial virus antiviral agents. Expert Opin. Investig. Drugs 10(2), 297–308 (2001).
  • •Review of RSV antivirals.
  • Torrence PF, Powell LD. The quest for an efficacious antiviral for respiratory syncytial virus. Antiviral Chem. Chemother. 13, 325–344 (2002).
  • •Review of RSV antivirals with emphasis on 2-5A antisense.
  • Easton AJ, Domachowske JB, Rosenberg HF. Animal pneumoviruses: molecular genetics and pathogenesis. Clin. Microbial Rev. 17, 390–412 (2004).
  • •Most recent review of pneumovirus biology.
  • Karron RA, Buonagurio DA, Georgiu AF, et al. Respiratory syncytial virus (RSV) SH-and G-proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc. Nad Acad Sci. USA 94, 13961–13966 (1997).
  • Techaarpornkul S, Barretto N, Peeples ME. Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. J. Viral 75, 6825–6834 (2001).
  • Bukreyev A, Whitehead SS, Murphy BR, Collins PL. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J. Viral 71,8973–8982 (1997).
  • Feldman SA, Audet S, Beeler JA. The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. J. Viral 74, 6442–6447 (2000).
  • Hallak LK, Spillmann D, Collins PL, Peeples ME. Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J. Viral 74,10508–10513 (2000).
  • Karger A, Schmidt U, Buchholz UJ. Recombinant bovine respiratory syncytial virus with deletions of the G or SH genes: G-and F-proteins bind heparin. J. Gen. Viral 82,631–640. (2001).
  • Martinez I, Melero JA. Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans. J. Gen. Viral 81, 2715–2722 (2000).
  • Gonzalez-Reyes L, Ruiz-Arguello MB, Garcia-Barreno B, et al. Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc. Nad Acad. Sci. USA 98,9859–9864 (2001).
  • Zimmer G, Budz L, Herrler G. Proteolytic activation of respiratory syncytial virus fusion protein. Cleavage at two furin consensus sequences. J. Biel Chem. 276, 31642–31650 (2001).
  • Schlender J, Zimmer G, Herrler G, Conzelmann KK. Respiratory syncytial virus (RSV) fusion protein subunit F2, not attachment protein G, determines the specificity of RSV infection. J. Viral 77, 4609–4616 (2003).
  • Calder LJ, Gonzalez-Reyes L, Garcia-Barren° B, et al. Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies. Virology 271, 122–131. (2000).
  • Lawless-Delmedico MK, Sista P, Sen R, et al. Heptad-repeat regions of respiratory syncytial virus Fl protein form a six-membered coiled-coil complex. Biochemistry 39,11684–11695 (2000).
  • Matthews JM, Young TF, Tucker SP, Mackay JP. The core of the respiratory syncytial virus fusion protein is a trimeric coiled coil. J. Viral 74,5911–5920 (2000).
  • Zhao X, Singh M, Malashkevich VN, Kim PS. Structural characterization of the human respiratory syncytial virus fusion protein core. Proc. Nad Acad Sci. USA 97, 14172–14177 (2000).
  • Melikyan GBRI\4, Hemmati H, Delmedico MK, Lambert DM, Cohen FS, Markosyan. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J. Cell Biol. 151,413–423 (2000).
  • Russell CJ, Jardetzky TS, Lamb RA. Membrane fusion machines of paramyxoviruses: capture of intermediates of fusion. Embo. J. 20,4024–4034 (2001).
  • Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89,263–273 (1997).
  • Judice JK, Tom JY, Huang W, et al. Inhibition of HIV type 1 infectivity by constrained a-helical peptides: implications for the viral fusion mechanism. Proc. Nad Acad Sci. USA 94,13426–13430 (1997).
  • Wild CT, Shugars DC, Greenwell TK, McDanal CB, Mathews TJ. Peptides corresponding to a predictive a-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Nad Acad. Sci. USA 91, 9770–9774 (1994).
  • Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Ann. Rev. Biochem. 69,531–569 (2000).
  • Baker KA, Dutch RE, Lamb RA, Jardetzky TS. Structural basis for paramyxovirus-mediated membrane fusion. Md. Cell. 3, 309–319 (1999).
  • Sergel-Germano T, McQuain C, Morrison T Mutations in the fusion peptide and heptad repeat regions of the Newcastle disease virus fusion protein block fusion. J. Viral. 68,7654–7658 (1994).
  • Spann KM, Tran KC, Chi B, Rabin RE, Collins PL. Suppression of the induction of a-, 13-, and y-interferons by the NS1 and N52 proteins of human respiratory syncytial virus in human epithelial cells and macrophages. J. Viral. 78,4363–4369 (2004).
  • Zhang B, Luxon A, Casola A, Garogalo RP, Jamaluddin M, Brasier AR. Expression of RSV-induced chemokine gene networks in lower airway epithelial cells revealed by cDNA microarrays. J. Viral. 75,9044–9058 (2001).
  • Black CP. Systematic review of the biology and medical management of respiratory syncytial virus infection. Re.Or. Care 48, 209–233 (2003).
  • Buckingham SC, Jafri HS, Bush AJ, et al. A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: efects on RSV quantity and clinical outcome. J. Infect. Dis. 185,1222–1228 (2002).
  • van Woensel JB, van Aalderen WM, de Weerd W, et al. Dexamethasone for treatment of patients mechanically ventilated for lower respiratory tract infection caused by respiratory syncytial virus. Thorax 58,383–387 (2003).
  • Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad spectrum antiviral activity of Virazole: 1-P-D-ribofuranosy1-1,2,4-triazole-3-carboxamide. Science 177, 705–706 (1972).
  • Eriksson B, Helgstrand E, Johansson NG, et al. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob. Agents Chemother. 11,946–951 (1977).
  • Wray SK, Gilbert BE, Knight V. Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antiviral Res. 5,39–48 (1985).
  • Toltzis P, O'Connell K, Patterson JL. Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription. Antimicrob. Agents Chemother. 32, 492–497 (1988).
  • Cassidy LF, Patterson JL. Mechanism of La Crosse virus inhibition by ribavirin. Antimicrob. Agents Chemother. 33, 2009–2011 (1989).
  • Rankin JT, Eppes SB, Antczak JB, Joklik WK. Studies on the mechanism of the antiviral activity of ribavirin against reovirus. Virology 168,147–158 (1989).
  • Goswami BB, Borek E, Sharma OK, Fujitaki J, Smith RA. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem. Biophys. Res. Commun. 89,830–836 (1979).
  • Canonic° PG. Ribavirin. A review of efficacy, toxicity and mechanisms of antiviral activity. Antibiotics 4,161–186 (1983).
  • Scheidel LM, Stollar V. Mutations that confer resistance to mycophenolic acid and ribavirin on sindbis virus map to the nonstructural protein NSP1. Virology 181, 490–499 (1991).
  • Gilbert BE, Knight V. Biochemistry and clinical applications of ribavirin. Antimicrob. Agents Chemother. 30, 201–205 (1986).
  • De Clercq E, Cools M, Balzarini J, et al. Antiviral activities of 5-ethyn1-1-13-ribofuranosylimidazole-4-carboxamide and related compounds. Antimicrob. Agents Chemother. 35,679–684 (1991).
  • Crotty S, Cameron CE, Andino R. Ribavirin's antiviral mechanism of action: lethal mutagenesis? J. MoL Med 80,86–95 (2002).
  • Domingo E, Holland JJ. RNA virus mutations and fitness for survival. Ann. Rev. Microbial. 51,151–178 (1977).
  • Crotty S, Maag D, Arnold JJ, et al. The broad spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nature Med. 6,1375–1379 (2000).
  • Maag D, Castro C, Hong Z, Cameron CE. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. BioL Chem. 276,46094–46098 (2001).
  • Severson WE, Schmaljohn CS, Javadian A, Jonsson CB. Ribavirin causes error catastrophe during Hantaan virus replication. J. Viral. 77,481–488 (2003).
  • Zhang Y, Jamaluddin M, Wang S, et al. Ribavirin treatment upregulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J. Viral. 77,5933–5947 (2003).
  • •Use of microarrays to understand ribavirin's mechanism of action.
  • Markland W, McQuaid TJ, Jain J, Kwong AD. Broad spectrum antiviral activity of the IMP dehydrogenase inhibitor VS-497: a comparison with ribavirin and demonstration of antiviral additivity with a-interferon. Antimicrob. Agents Chemother. 44,859–866 (2000).
  • Roberts NA, Appleton R, Scott R CellCept is active against RSV disease in mice. 14th International Conference on Antiviral Research. Seattle, WA, USA 8–13 April 2001.
  • Lin CC, Philips L, Xu C, Yeh LT Pharmacokinetics and safety of Viramidine'rm, a prodrug of ribavirin, in healthy volunteers. J. Clin. PharmacoL 44, 265–275 (2004).
  • Harki DA, Graci JD, Korneeva VS, et al. Synthesis and antiviral evaluation of a mutagenic and nonhydrogen bonding ribonucleoside analog: 14-D-ribofuranosy1-3-nitropyrrole. Biochemistry 41,9026–9033 (2002).
  • Hruska JF, Bernstein JM, Douglas RG, Hall CB. Effects of ribavirin on respiratory syncytial virus. Antimicrob. Agents Chemother. 17, 770–775 (1980).
  • Hruska JF, Morrow PE, Suffin Sc, Douglas RG. In vivo inhibition of respiratory syncytial virus by ribavirin. Antimicrob. Agents Chemother. 21, 125–130 (1982).
  • Ding WD, Mitsner B, Krishnamurthy G, et al. Novel and specific respiratory syncytial virus inhibitors that target virus fusion. J. Med. Chem. 41,2671–2675 (1998).
  • Gazumyan A, Mitsner B, Ellestad GA. Novel anti-RSV dianionic dendrimer-like compounds: design, synthesis and biological evaluation. Curr. Pharm. Des. 6, 525–546 (2000).
  • Huntley CC, Weiss WJ, Gazumyan A, et al. RFI-641, a potent respiratory syncytial virus inhibitor. Antimicrob. Agents Chemother. 46,841–847 (2002).
  • Razinkov V, Gazumyan A, Nikitenko A, Ellestad G, Krishnamurthy G. RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein. Chem. Biol. 8,645–659. (2001).
  • Razinkov V, Huntley CC, Ellestad G, Krishnamurthy G. RSV entry inhibitors block F-protein mediated fusion with model membranes. Antiviral Res. 55, 189–200 (2002).
  • Gazumyan A. Mechanism of action of a novel inhibitor of respiratory syncytial virus. 12th International Conference on Antiviral Research. Jerusalem, Israel, 5–7 April (1999).
  • Morton CJ, Cameron R, Lawrence LJ, et al. Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F-protein and a syncytium formation assay. Virology 311,275–288 (2003).
  • Weiss WJ, Murphy T, Lynch ME, et al. Inhalation efficacy of RFI-641 in an african green monkey model of RSV infection. J. Med. Primatol. 32,82–88 (2003).
  • Sudo K, Watanabe W, Konno K, et al. Efficacy of RD3-0028 aerosol treatment against respiratory syncytial virus infection in immunosuppressed mice. Antimicrob. Agents Chemother. 43,752–757 (1999).
  • Sudo K, Konno K, Watanabe W, Shigeta S, Yokota T Mechanism of selective inhibition of respiratory syncytial virus by a benzodithiin compound (RD3-0028). Microbial Immunol 45,531–537 (2001).
  • Kimura K, Mori S, Tomita K, et al. Antiviral activity of NMS03 against respiratory syncytial virus infection in vitro and in vivo. Antiviral Res. 47,41–51 (2000).
  • Nakamura M, Terada M, Kamada M, Yokono A, Nakamori S, Ohno T Mechanistic effect of NMS03 on replication of human immunodeficiency virus. Antiviral Chem. Chemother. 14,171–176 (2003).
  • McKimm-Breschkin J. VP-14637 ViroPharma. Curr. Opin. Investig. Drugs 1, 425–427 (2000).
  • Douglas JL, Panis ML, Ho E, et al. Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. J. Viral. 77,5054–5064 (2003).
  • Andries K, Moeremans M, Gevers T, et al. Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Antiviral Res. 60,209–219 (2003).
  • Wyde P, Chetty SN, Timmerman P, Gilbert BE, Andries K. Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection. Antiviral Res. 60, 221–231 (2003).
  • Andries K. R-170591 interferes with RSV fusion. Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada, 17–20 September 2000.
  • Cianci C, Yu KL, Combrink K, et al. Orally-active fusion inhibitor of respiratory syncytial virus. Antimicrob. Agents Chemother. 48,413–422 (2004).
  • Cianci C, Yu KL, Sin N, et al. Discovery of a new class of orally-active respiratory syncytial virus inhibitors. Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA, 27–30 September 2002.
  • Pastey MK, Crowe JE Jr, Graham BS. RhoA interacts with the fusion glycoprotein of respiratory syncytial virus and facilitates virus-induced syncytium formation. J. Viral 73,7262–7270 (1999).
  • Pastey MK, Gower TL, Spearman PWJr, Graham BS, Crowe JE. A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3. Nature Med 6, 35–40 (2000).
  • Gower TL,Graham BS. Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. Antimicrob. Agents Chemother. 45,1231–1237 (2001).
  • Carter M. Small-molecule inhibitors of RSV — novel approaches. Small-Molecule Inhibitor Conference on Future Antivirals. London, UK 12–13 November 2003.
  • Arrow Therapeutics. Benzodiazepine Derivatives and Pharmaceutical Compositions Containing Them. (2004).
  • Player MR, Torrence PE The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation. Pharmacol Therapeutics 78,55–113 (1998).
  • Leaman DW, Longano FJ, Okicki JR, et al. Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense. Virology 292,70–77 (2002).
  • Hannon GJ. RNA interference. Nature 418,244–251 (2002).
  • Bitko V, Batik S. Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild-type negative-strand RNA viruses. BMC Microbial, 34 (2001).
  • Batik S. Control of nonsegmented negative-strand RNA virus replication by siRNA. Virus Res. 102,27–35 (2004).
  • •Review of short interfering RNA applications for RSV and other RNA viruses
  • Caplen NJ. RNAi as a gene therapy approach. Expert Opin. Biol. Them 3(4), 575–586 (2003).
  • Randall G, Rice CM. Interfering with hepatitis C virus RNA replication. Virus Res. 102,19–25 (2004).
  • Bitko V, Oldenburg A, Garmon NE, Barik S. Profilin is required for viral morphogenesis, syncytium formation, and cell-specific stress fiber induction by respiratory syncytial virus. BMC Microbial. 3,9 (2003).
  • Wild C, Oas T, McDanal C, Bolognesi D, Mathews T A synthetic peptide inhibitorof human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc. Natl Acad. Sci. USA 89, 10537–10541 (1992).
  • Rapaport D, Ovadia M, Shai Y. A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus-cell fusion: an emerging similarity with functional domains of other viruses. Embo. J. 14,5524–5531 (1995).
  • Yao Q, Compans RW. Peptides corresponding to the heptad repeat sequence of human parainfluenza virus fusion protein are potent inhibitors of virus infection. Virology 223,103–112 (1996).
  • Young JK, Hicks RP, Wright GE, Morrison TG. Analysis of a peptide inhibitor of paramyxovirus (NDV) fusion using biological assays, NMR, and molecular modeling. Virology 238, 291–304 (1997).
  • Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Med. 4,1302–1307 (1998).
  • Lambert DM, Barney S, Lambert AL, et al. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc. Natl Acad. Sci. USA 93,2186–2191 (1996).
  • Budge PJ, Li Y, Beeler JA, Graham BS. RhoA-derived peptide dimers share mechanistic properties with other polyanionic inhibitors of respiratory syncytial virus (RSV), including disruption of viral attachment and dependence on RSV G. J. Viral. 78, 5015–5022 (2004).
  • Everard ML. Inhalation therapy for infants. Adv. Drug Devel. Rev. 55, 869–878 (2003).
  • Prince GA, Mathews A, Curtis SJ, Porter DD. Treatment of respiratory syncytial virus bronchiolitis and pneumonia in a cotton rat model with systemically administered monoclonal antibody (palivizumab) and glucocorticosteroid. J. Infect. Dis. 182,1326–1330 (2000).
  • •Evidence that both an antiviral agent and animmune modulator will be necessary to combat RSV disease.
  • Garrison MM, Christakis DA, Harvey E, Cummings P, Davis RL. Systemic corticosteroids in infant bronchiolitis: a meta-analysis. Pediatrics 105,1–6 (2000).
  • Homsleth A, Loland L, Larsen LB. Cytokines and chemokines in respiratory secretion and severity of disease in infants with respiratory syncytial virus (RSV) infection. J. Clin. Vir. 21,163–170 (2001).
  • Kimpen JLL. Prevention and treatment of respiratory syncytial virus bronchiolitis and postbronchiolitic wheezing. Respir Res. 3, 40–45 (2002).

Websites

  • MICROBIOTIX, press releases and news. 5 March 2002 press release. www.microbiotix.com/news.htm (Accessed July 2004)
  • ViroPharma Incorporated www.viropharma.com/index.htmwww.iddb. corn (Accessed July 2004)
  • Investigational Drugs Database www.iddb.com (Accessed July 2004) Great source for information on drugs in development.
  • Biota, Inc. Homepage www.biota.com.au (Accessed July 2004)
  • Arrow Therapeutics press release June 2004 www.arrowt.co.uk (Accessed July 2004)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.